Denosumab is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.
One shot of Prolia® (denosumab) every six months is proven to help women with postmenopausal osteoporosis at high risk for fracture strengthen their bones.
Denosumab (Prolia, Xgeva) monoclonal antibody therapy side effects, how it's given, how it works, precautions and self care tips for treatment of osteoporosis, ...
Nov 15, 2016 ... Denosumab Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus.
Your guide to the targeted cancer drug denosumab how you have it, when you have it and other important information.
Oct 4, 2017 ... Easy to read patient leaflet for Denosumab Injection (Prolia). Includes indications, proper use, special instructions, precautions, and possible ...
Jun 16, 2017 ... Prolia (denosumab) is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL (receptor activator of nuclear factor ...
Drugs Today (Barc). 2008 Jan;44(1):7-21. doi: 10.1358/dot.2008.44.1.1178467. Denosumab: RANKL inhibition in the management of bone loss. Hamdy NA(1).
UpToDate, electronic clinical resource tool for physicians and patients that provides information on Adult Primary Care and Internal Medicine, Allergy and ...